Epithalon (also spelled Epitalon or Epithalone) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. With a molecular weight of 390.35 g/mol and CAS number 307297-39-8, it is a synthetic analog of epithalamin, a polypeptide extract derived from bovine pineal glands. Epithalon has attracted significant interest in the longevity research community for its reported ability to activate telomerase, the enzyme responsible for maintaining telomere length at chromosome ends, and to restore melatonin production in aging organisms. However, nearly all published research originates from a single research group, and the compound has never undergone Western-standard randomized controlled trials in humans.
Primary areas of research include:
- Telomerase activation and telomere elongation in somatic cells
- Melatonin production and circadian rhythm restoration in aging populations
- Antioxidant defense and DNA repair pathway activation
- Immune system modulation and geroprotection
- Anti-tumor effects in specific animal models
What Is Epithalon?
Epithalon was developed as a synthetic replacement for epithalamin, a crude extract of bovine pineal glands that Khavinson and colleagues had studied since the 1970s. Epithalamin showed geroprotective effects in animal models but was impractical for standardized use due to the variability inherent in biological extracts. Through peptide sequencing work, Khavinson's team identified the tetrapeptide Ala-Glu-Asp-Gly as the biologically active core of the extract, and synthesized it as a discrete compound for further study.
The research context is important to understand. The overwhelming majority of published Epithalon research originates from Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, with additional contributions from collaborators including Vladimir Anisimov at the N.N. Petrov Research Institute of Oncology. While this body of work spans several decades and hundreds of publications, the absence of robust independent replication by unaffiliated Western laboratories is a significant limitation that must inform any assessment of the compound's efficacy.
Despite these caveats, the proposed biological activities of Epithalon are notable:
- Activation of telomerase and elongation of telomeres in human somatic cells
- Restoration of melatonin secretion and circadian rhythm normalization in elderly subjects
- Upregulation of endogenous antioxidant enzymes including superoxide dismutase
- Reduction in age-related chromosomal aberrations in animal models
- Extension of maximum lifespan in SHR mice (approximately 13%)
- Inhibition of spontaneous tumor development in certain transgenic mouse strains
How It Works
Telomerase Activation
The most cited mechanism for Epithalon is its reported activation of telomerase through upregulation of the human telomerase reverse transcriptase (hTERT) gene. Telomeres, the protective nucleotide caps at the ends of chromosomes, shorten with each cell division, and their progressive erosion is considered a fundamental hallmark of cellular aging. Telomerase is the enzyme that can add telomeric repeats back to chromosome ends, but its expression is silenced in most adult somatic cells.
In the foundational 2003 study by Khavinson, Bondarev, and Butyugov, addition of Epithalon to cultures of telomerase-negative human fetal fibroblasts induced expression of the hTERT catalytic subunit, reactivated telomerase enzymatic activity, and produced measurable telomere elongation. The authors proposed that Epithalon achieves this by binding to methylated cytosine residues in DNA and interacting with linker histone proteins H1.3 and H1.6, thereby modifying chromatin structure around the hTERT promoter region and de-repressing gene expression.
A 2025 study by Al-Dulaimi and colleagues provided the first significant independent examination of Epithalon's telomere effects. This work demonstrated dose-dependent telomere elongation in normal human cell lines through hTERT upregulation. Notably, the study also found that Epithalon increased telomere length in cancer cell lines through activation of the Alternative Lengthening of Telomeres (ALT) pathway, an observation with important safety implications that warrants further investigation.
Pineal Gland and Melatonin Regulation
Epithalon's origins in pineal gland research are reflected in its demonstrated effects on melatonin synthesis. The pineal gland is the primary producer of melatonin, the neurohormone that regulates circadian rhythms, and pineal function declines progressively with age, contributing to the disrupted sleep patterns, impaired immune function, and increased oxidative stress associated with aging.
Research from Khavinson's group showed that Epithalon can restore the nocturnal melatonin peak in both aged rhesus monkeys and elderly human subjects with documented pineal insufficiency. Khavinson's group has also reported that Epithalon influences circadian regulation, with studies in elderly subjects and animal models showing restoration of the nocturnal melatonin peak following treatment.
These melatonin-related effects may be responsible for many of the downstream benefits attributed to Epithalon, as melatonin itself is a potent antioxidant, immunomodulator, and anti-inflammatory agent. It is reasonable to hypothesize that a substantial portion of Epithalon's reported geroprotective properties may be mediated through melatonin restoration rather than through direct cellular effects.
Antioxidant and DNA Repair Properties
Epithalon has been reported to upregulate endogenous antioxidant enzymes, including superoxide dismutase and catalase, while reducing markers of lipid peroxidation in animal models. By reducing oxidative damage to cellular macromolecules, including DNA, proteins, and membrane lipids, Epithalon may lower the cumulative burden of oxidative stress that drives age-related deterioration.
In multiple mouse strains, Epithalon treatment reduced the incidence of chromosomal aberrations by 17.9% to 30.1% compared to age-matched controls, with the range varying across SAM and SHR strains. The proposed mechanism involves Epithalon's interaction with chromatin structure: by binding to linker histones and methylated DNA regions, it may facilitate access of DNA repair enzymes to damaged sites and restore more youthful patterns of gene expression. However, the precise molecular pathways connecting a simple tetrapeptide to these broad epigenetic effects remain incompletely characterized.
Immune System Modulation
Age-related immune decline (immunosenescence) is a major contributor to increased infection susceptibility, cancer risk, and chronic inflammation in the elderly. Epithalon, along with its parent extract epithalamin, has been reported to improve immunological parameters in both animal models and elderly human subjects.
In the clinical studies conducted by Khavinson's group, treatment with epithalamin (and later Epithalon) was associated with improved T-cell function, normalized cytokine profiles, and reduced incidence of acute respiratory infections. Combined treatment with epithalamin and thymalin (a thymus-derived peptide) produced the most pronounced immunological improvements, with acute respiratory disease incidence decreasing 2.0 to 2.4-fold compared to controls in an observational study of elderly patients. Whether these immune benefits are direct or secondary to melatonin restoration and reduced oxidative stress remains an open question.
Dosage Protocols
No FDA-approved dosing guidelines exist for Epithalon. The following information is derived from published research protocols and community reports:
Research Protocol Dosing:
- Standard protocol: 5 to 10 mg per day via subcutaneous injection for 10 to 20 consecutive days
- Cycling: Repeat once or twice per year, with 4 to 6 month intervals between cycles
- Higher doses: Some community protocols report doses above 10 mg/day, though no published data supports increased efficacy beyond the standard range
Community Dosing Protocols:
- Conservative: 5 mg subcutaneously once daily for 20 days, twice per year
- Moderate: 10 mg subcutaneously once daily for 10 days, twice per year
- Split dosing: 5 mg twice daily (morning and evening) for 10 days
Timing: Evening or bedtime administration is commonly recommended to align with natural melatonin rhythms, particularly for individuals using Epithalon with the intent of supporting circadian regulation. Epithalon is also reviewed in the [best peptides for sleep guide](/guides/best-peptides-for-sleep).
Cycling Rationale: The intermittent protocol, short treatment courses separated by months-long breaks, is based on the hypothesis that Epithalon triggers regulatory cascades that persist after the peptide itself is cleared, rather than requiring continuous receptor occupancy. This is consistent with the bioregulation framework that underpins Khavinson's research, though it has not been validated through pharmacokinetic studies in humans.
How to Use / Administration Methods
Subcutaneous Injection (Standard Route): Epithalon is administered via subcutaneous injection into the abdominal region, thigh, or upper arm. Rotate injection sites systematically to prevent lipohypertrophy. Use an insulin syringe for accurate dosing.
Sublingual Administration: Some research protocols have used sublingual Epithalon delivery, including the melatonin study involving 75 women. Bioavailability via sublingual route compared to injection has not been rigorously characterized.
Intranasal Administration: Nasal spray formulations have been explored in limited research settings. Absorption and efficacy data for intranasal delivery are insufficient to make dosing recommendations.
Reconstitution: Epithalon is supplied as a lyophilized (freeze-dried) white powder requiring reconstitution before injection.
- Allow the vial to reach room temperature
- Draw bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe
- Inject the water slowly along the interior vial wall, do not jet directly onto the powder
- Gently swirl until fully dissolved; do not shake
- Inspect the solution for clarity. It should be clear and colorless
Common Reconstitution Ratio:
- 10 mg Epithalon + 1 mL bacteriostatic water = 10 mg/mL (1:1 ratio)
- Each 0.1 mL (10 units on an insulin syringe) = 1 mg
Storage:
- Lyophilized powder: Stable for up to 3 years at -20°C, up to 2 years at 2 to 8°C
- Reconstituted solution: Refrigerate at 2 to 8°C, use within 6 weeks, protect from light
- Discard if solution becomes cloudy, discolored, or contains particulate matter
Results Timelines
During Treatment (Days 1 to 20):
- Improved sleep quality and circadian rhythm regulation (often noted within the first week, likely mediated by melatonin effects)
- Subjective reports of improved energy and mood
- Potential reduction in oxidative stress markers
Weeks to Months Post-Cycle:
- Melatonin production changes may persist for weeks to months beyond the treatment period
- Any telomere-related effects would not be subjectively noticeable and would require laboratory measurement to detect
- Immune parameter improvements reported in clinical studies emerged over weeks to months
Long-Term (Multiple Cycles Over Years):
- The 6 to 8-year observational studies from Khavinson's group reported reduced mortality, decreased cardiovascular events, and lower cancer incidence in treated elderly patients
- These long-term results, while notable, come from unblinded observational studies rather than randomized controlled trials
The critical distinction with Epithalon is that most purported benefits (telomere elongation, reduced biological aging) are not subjectively perceptible. Unlike peptides that produce obvious effects on body composition, wound healing, or energy levels, Epithalon's primary actions occur at the molecular level and would require biomarker testing to verify.
Research Evidence
The evidence base for Epithalon requires careful contextual evaluation. The quantity of published research is substantial, spanning cell culture, animal models, and human observational studies, but the quality and independence of this research present significant limitations.
Telomerase Activation (In Vitro)
The 2003 Khavinson study demonstrating telomerase activation in human fetal fibroblasts is the most frequently cited finding. Addition of Epithalon to telomerase-negative cells induced hTERT expression, restored telomerase activity, and produced telomere elongation. This was the first demonstration that a short synthetic peptide could reactivate telomerase in somatic cells.
A 2025 study by Al-Dulaimi et al. provided more recent data, showing dose-dependent telomere elongation in normal human cell lines via hTERT upregulation. This study also revealed ALT pathway activation in cancer cells exposed to Epithalon, a finding that deserves attention given theoretical concerns about telomerase activation and oncogenesis.
Animal Longevity Studies
Anisimov and colleagues conducted several lifespan studies in mouse models:
- In female Swiss-derived SHR mice, monthly Epithalon injections (1.0 mcg/mouse for 5 consecutive days) did not reduce total spontaneous tumor incidence but inhibited leukemia development 6-fold and increased mean lifespan compared to controls
- In HER-2/neu transgenic mice (a breast cancer model), Epithalon decreased the incidence of breast adenocarcinomas by 1.6-fold and lung metastases by 2-fold
- In the SHR mouse study, Epithalon increased maximum lifespan by approximately 13%
These animal results are intriguing but require important caveats: the studies were conducted by close collaborators of the compound's developer, sample sizes were modest, and independent replication by unaffiliated laboratories has not been published.
Human Observational Studies
The most ambitious human evidence comes from a 6 to 8-year observational study of 266 elderly patients treated with epithalamin, thymalin, or both. Key findings included:
- 1.6 to 1.8-fold decreased mortality in the epithalamin-treated group
- 2.5-fold decreased mortality with combined thymalin plus epithalamin treatment
- 2.0 to 2.4-fold reduction in acute respiratory disease incidence
- Reduced clinical manifestations of ischemic heart disease, hypertension, and osteoporosis
A separate cohort treated with both peptides annually for 6 years showed a 4.1-fold decrease in mortality compared to controls. A 15-year follow-up study reported continued mortality reductions in treated groups.
These results are striking but must be interpreted with significant caution: the studies were not randomized controlled trials, blinding was not described, and the magnitude of the reported effects, a 4.1-fold mortality reduction, would be historically unprecedented for any single intervention and is difficult to reconcile with the modest biological effects of a simple tetrapeptide. All published human clinical data on epithalon comes from a single research group (Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology), with no independent replication. A 4.1-fold mortality reduction would be among the largest effects ever documented for any intervention in the history of medicine.Research Limitations
The core limitation of the Epithalon evidence base cannot be overstated: the research literature is dominated by a single laboratory group with a direct interest in the compound's success. The absence of large-scale, double-blind, placebo-controlled trials by independent investigators means that even the most compelling findings remain preliminary. Western pharmaceutical and academic institutions have shown limited interest in pursuing Epithalon research, which may reflect skepticism about the claimed effects, difficulties with intellectual property, or simply lack of commercial incentive for a non-patentable tetrapeptide.
Stacking
Epithalon's proposed mechanisms, telomerase activation, melatonin regulation, and antioxidant support, are theoretically complementary to several other longevity-oriented compounds. However, no formal studies have examined Epithalon in combination with other peptides or supplements.
Epithalon + Thymosin Alpha 1
The combination with the strongest historical basis, given that Khavinson's own studies combined pineal peptides (epithalamin/Epithalon) with thymic peptides (thymalin/Thymosin Alpha 1). The combined treatment produced more pronounced immune and mortality benefits than either peptide alone in observational studies. The rationale is complementary target systems: Epithalon addresses pineal/neuroendocrine aging while Thymosin Alpha 1 targets thymic/immune aging.
Epithalon + NAD+ Precursors (NMN or NR)
A theoretically sound combination addressing different hallmarks of aging. NAD+ precursors support mitochondrial energy metabolism and sirtuin-mediated DNA repair, while Epithalon targets telomere maintenance and pineal regulation. These mechanisms are largely non-overlapping.
Epithalon + SS-31 (Elamipretide)
Combining telomere-level cellular protection (Epithalon) with mitochondrial membrane protection (SS-31) addresses two distinct but converging drivers of cellular aging. SS-31 has a substantially stronger clinical evidence base, making it the more validated component in this combination. For a direct comparison, see Epithalon vs SS-31.
Epithalon + GHK-Cu
GHK-Cu promotes tissue remodeling, wound healing, and antioxidant gene expression. Combined with Epithalon's reported effects on DNA repair and antioxidant enzyme upregulation, the two peptides may provide additive antioxidant and regenerative support. No direct research supports this combination.
General Caution: All stacking protocols are speculative and based on mechanistic reasoning rather than clinical evidence. Establishing individual response to each compound alone before combining is advisable.
Reconstitution, Storage & Prep
Epithalon is supplied as a lyophilized white powder requiring reconstitution before subcutaneous injection.
Reconstitution Process:
- Allow the vial to reach room temperature before opening
- Use bacteriostatic water (0.9% benzyl alcohol) as the reconstitution vehicle
- Draw the appropriate volume of bacteriostatic water into an insulin syringe
- Insert the needle through the stopper and inject water slowly along the interior vial wall
- Gently swirl until powder is fully dissolved, do not shake
- Inspect the solution; it should be clear and colorless
Reconstitution Ratio (1:1):
- 10 mg Epithalon + 1 mL bacteriostatic water = 10 mg/mL
- For a 5 mg dose: draw 0.5 mL (50 units on an insulin syringe)
- For a 10 mg dose: draw 1.0 mL (100 units on an insulin syringe)
Storage Guidelines:
- Lyophilized (unreconstituted): Up to 3 years at -20°C; up to 2 years at 2 to 8°C
- Reconstituted solution: Store at 2 to 8°C (refrigerator); use within 6 weeks
- Protect from light at all times
- Do not freeze reconstituted solution
- Discard if the solution becomes cloudy, discolored, or contains particulate matter
Side Effects
Epithalon's safety profile appears favorable based on the available data, though this data is limited and originates predominantly from a single research group.
Commonly Reported:
- Injection site reactions: mild redness, swelling, or irritation at the injection site (consistent with most subcutaneous peptide injections)
- Drowsiness or fatigue: likely related to melatonin modulation, particularly with evening dosing
- Mild headache: reported infrequently and typically transient
Rarely Reported:
- Gastrointestinal upset
- Allergic reactions (no severe cases documented in published research)
Serious Adverse Events: No serious adverse events have been reported in published studies. Long-term observational studies spanning up to 15 years in elderly patients did not document significant adverse effects, though these studies were not designed as formal safety trials.
Theoretical Concerns:
- Telomerase and cancer risk: Telomerase reactivation is a hallmark of most cancers, and any compound that activates telomerase raises legitimate questions about potential tumor promotion. The 2025 study demonstrating ALT pathway activation in cancer cell lines adds to this concern. While animal studies from Khavinson's group actually showed reduced tumor incidence with Epithalon treatment, individuals with active or undetected malignancies should exercise particular caution.
- Immunogenicity: The FDA has identified Epithalon among peptides that may pose immunogenicity risks, the potential for the body to mount an immune response against the peptide itself.
Sourcing Risks: Epithalon sourced from unregulated research chemical suppliers carries inherent risks of contamination, incorrect dosing, and unknown impurity profiles that are separate from the compound's intrinsic safety characteristics. Independent third-party testing is advisable for any research peptide.
Legal Status / FDA
Epithalon is not FDA-approved for any medical indication and has never entered the FDA's formal drug approval process.
United States:
- Not approved as a drug, food, or dietary supplement for human consumption
- Sold as a research chemical labeled "not for human use"
- The FDA has identified Epithalon among peptides posing immunogenicity concerns
- Not DEA-scheduled; possession is not a criminal offense
- Not available through U.S. compounding pharmacies under current regulatory framework
Russia:
- Epithalamin (the bovine pineal extract from which Epithalon was derived) has been used clinically in Russia, where the regulatory environment for peptide bioregulators differs substantially from Western frameworks
- Epithalon and related bioregulatory peptides have broader acceptance within Russian clinical practice than in Western medicine
International:
- Regulations vary significantly by jurisdiction
- No major Western regulatory body (EMA, TGA, Health Canada) has approved Epithalon for therapeutic use
- Available internationally through online research peptide suppliers
Regulatory Outlook: In February 2026, U.S. Health and Human Services officials discussed potentially reclassifying certain peptides from Category 2 to Category 1 to restore compounding pharmacy access, though this reclassification has not occurred as of this writing and it is unclear whether Epithalon would be affected.
Sports / WADA
Epithalon is not explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List as of 2026. Unlike peptide hormones and growth factors covered under Section S2, Epithalon does not directly manipulate hormonal or growth factor pathways.
However, athletes should consider the following:
- WADA's S0 category prohibits "non-approved substances", pharmacological agents not approved by any regulatory authority for human use. Epithalon, as an unapproved research compound, could potentially fall under this broad prohibition depending on the context of use.
- Individual sports organizations and national anti-doping agencies may apply broader restrictions than the WADA Prohibited List itself.
- The absence of a specific ban does not guarantee protection from sanctions under non-specific prohibitions.
- Athletes subject to anti-doping testing should consult with their relevant anti-doping authority or sports federation before using Epithalon.
The compound's mechanism of action, acting at the level of gene expression and telomere biology rather than directly enhancing performance, makes it a less obvious target for anti-doping enforcement than anabolic agents or peptide hormones, but regulatory categorization is ultimately a policy decision rather than a scientific one.
Conclusion
Epithalon occupies a fascinating but uncertain position in the longevity peptide landscape. The theoretical framework is appealing: a simple, low-toxicity tetrapeptide that reactivates telomerase, restores melatonin production, and slows cellular aging. The published research spans decades, includes cell culture, animal, and human data, and presents a coherent narrative of geroprotective benefit.
The critical weakness is independence. Nearly all published Epithalon research originates from a single laboratory group with a direct scientific and potentially commercial interest in positive results. The reported effect sizes in human observational studies, multi-fold mortality reductions, are extraordinary claims that, by the standards of evidence-based medicine, require extraordinary evidence. That evidence, in the form of large, randomized, double-blind, placebo-controlled trials conducted by independent investigators, does not exist.
For individuals considering Epithalon, the honest assessment is this: the compound may do what its proponents claim, but the evidence is insufficient to conclude that it does. The safety profile appears favorable based on available data, the theoretical mechanisms are biologically plausible, and the dosing protocols are straightforward. But the distance between "biologically plausible" and "clinically proven" is the entire length of modern pharmaceutical development, a journey Epithalon has barely begun in the Western scientific framework.
The most scientifically defensible approach is to regard Epithalon as an early-stage research compound with intriguing but unvalidated potential, and to weigh its use against the availability of better-characterized longevity interventions including exercise, caloric optimization, sleep hygiene, and compounds with stronger independent evidence bases such as NAD+ precursors and metformin.